Pharmacist-Led Continuous Glucose Monitoring for Prediabetes

Recruiting now

Conditions studied: Prediabetes

In brief

The goal of this observational study is to determine if a pharmacist-led program involving continuous glucose monitoring (CGM) improves glucose control and health behavior in people with prediabetes. The main questions it aims to answer are: 1. Determine impact of pharmacist-led CGM on glycemic control in people with prediabetes. Researchers will compare change in hemoglobin A1c at 12 weeks with pharmacist-led CGM versus a historical cohort of subjects with prediabetes receiving no CGM. The investigators will also assess change in CGM-derived glycemic metrics from baseline to end of the CGM wear period in the intervention group. 2. Evaluate impact of pharmacist-led CGM on health behavior change in people with prediabetes in the intervention group. Participants will be asked to complete the Summary of Diabetes Self-Care Activities Measure (SDSCA) and 36-Item Short Form Health Survey (SF-36) at baseline, at the end of week 4, and at the end of the study so that researchers can measure the effects in the intervention group on health behavior change.

Key facts

Study ID

NCT07529366

Run by

University of South Florida

People needed

40

Starts

2026-09-01

Expected to finish

2027-07-31

Last updated by the study team

2026-08-10

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• adults 18-70 years of age
• prediabetes (HbA1c 5.7-6.4%)
• compatible smartphone with the Dexcom Stelo sensor system
• have not have worn a CGM in the last 6 months prior to enrollment

You may not qualify if…

• any of the following forms of diabetes: type 1 diabetes, type 2 diabetes, monogenic diabetes, cystic fibrosis-related diabetes, post- transplant diabetes, latent autoimmune diabetes
• problematic hypoglycemia in the prior 6 months [defined as recurrent (more than one) level 2 hypoglycemic events (glucose <54mg/dL ) that persist despite multiple attempts to adjust medication(s) and/or modify the diabetes/treatment plan or a history of one level 3 hypoglycemic event (glucose <54mg/dL) characterized by altered mental and/or physical state requiring third-party assistance for treatment of hypoglycemia]
• pregnant, or planning to become pregnant during the study time frame
• currently receiving or planned to receive dialysis during the study time frame - current use of systemic steroids for any condition
• a known allergy to medical grade adhesives,
• use of any CGM device in the past 6 months
• history of a diagnosed eating disorder
• current use of a second-generation antipsychotic at the time of consent (aripiprazole, asenapine, brexpiprazole, cariprazine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone)
• subjects lacking capacity to provide informed consent

Where it is running

• USF Health Department of Family Medicine - Morsani Center for Advanced Health Care — Tampa, Florida, United States (enrolling)
• USF Health Department of Family Medicine - University Partnership Center — Tampa, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.